Delving into the Latest Updates on KAEL-GemVax Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Digestive System Disorders

Nervous System Diseases

Therapeutic vaccine

Synthetic peptide

Synthetic peptide vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	3
Endocrinology and Metabolic Disease	1
Immune System Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Therapeutic vaccine	2
Synthetic peptide	1
Synthetic peptide vaccine	1

Top 5 Target	Count

Mitochondrial proteins	1
TERT(Telomerase reverse transcriptase)	1

This study involves testing of the medicine LTX-315 combined with a cancer vaccine (GV1001). This will be tested in patients that have had surgery with curative intent for malignant tumour.
GV1001 is a peptide vaccine in development to treat cancer. An adjuvant, is required to start the immune response in the body to have effect of GV-1001.
LTX-315, also a peptide, in development for cancer treatment. In this study, the investigators wish to find out whether LTX-315 can make GV1001 more effective at stimulating the immune system.

Start Date01 Aug 2010

Sponsor / Collaborator

Lytix Biopharma AS

[+1]

NCT00514072 / Unknown statusPhase 2

A Double-Blind Randomized Phase 2.5 Trial of ONY-P1 Vaccine Versus Placebo in Men With D0 Prostate Cancer Following Limited Androgen Ablation

RATIONALE: Vaccines made from tumor cells may help the body build an effective immune response to kill tumor cells.
PURPOSE: This randomized phase II trial is studying vaccine therapy to see how well it works compared with a placebo in treating patients with stage D0 prostate cancer.

Start Date01 Mar 2007

Sponsor / Collaborator

KAEL-GemVax Co., Ltd.

[+1]

100 Clinical Results associated with KAEL-GemVax Co., Ltd.

Login to view more data

0 Patents (Medical) associated with KAEL-GemVax Co., Ltd.

Login to view more data

2

Literatures (Medical) associated with KAEL-GemVax Co., Ltd.

01 Jul 2016·NeuroToxicologyQ2 · MEDICINE

Neural stem cells injured by oxidative stress can be rejuvenated by GV1001, a novel peptide, through scavenging free radicals and enhancing survival signals

Q2 · MEDICINE

Article

Author: Lee, Young Joo ; Lee, Eun-Hye ; Lee, Kyu-Yong ; Choi, Na-Young ; Yoon, Moon-Young ; Kim, Gabseok ; Park, Hyun-Hee ; Kim, Sangjae ; Yu, Hyun-Jung ; Koh, Seong-Ho

Oxidative stress is a well-known pathogenic mechanism of a diverse array of neurological diseases, and thus, numerous studies have attempted to identify antioxidants that prevent neuronal cell death. GV1001 is a 16-amino-acid peptide derived from human telomerase reverse transcriptase (hTERT). Considering that hTERT has a strong antioxidant effect, whether GV1001 also has an antioxidant effect is a question of interest. In the present study, we aimed to investigate the effects of GV1001 against oxidative stress in neural stem cells (NSCs). Primary culture NSCs were treated with different concentrations of GV1001 and/or hydrogen peroxide (H2O2) for various time durations. The H2O2 decreased the viability of the NSCs in a concentration-dependent manner, with 200μM H2O2 significantly decreasing both proliferation and migration. However, treatment with GV1001 rescued the viability, proliferation and migration of H2O2-injured NSCs. Consistently, free radical levels were increased in rat NSCs treated with H2O2, while co-treatment with GV1001 significantly reduced these levels, especially the intracellular levels. In addition, GV1001 restored the expression of survival-related proteins and reduced the expression of death-associated ones in NSCs treated with H2O2. In conclusion, GV1001 has antioxidant and neuroprotective effects in NSCs following treatment with H2O2, which appear to be mediated by scavenging free radicals, increasing survival signals and decreasing death signals.

01 Jun 2014·Neurobiology of AgingQ2 · MEDICINE

The novel vaccine peptide GV1001 effectively blocks β-amyloid toxicity by mimicking the extra-telomeric functions of human telomerase reverse transcriptase

Q2 · MEDICINE

Article

Author: Kim, Sangjae ; Lee, Young Joo ; Lee, Jessica Woojin ; Koh, Seong-Ho ; Lee, Kyu-Yong ; Lee, Eun-Hye ; Park, Hyun-Hee ; Lee, Sang-Hun ; Choi, Na-Young

GV1001 is a 16-amino-acid vaccine peptide derived from the human telomerase reverse transcriptase sequence. We investigated the effects of GV1001 against β-amyloid (Aβ) oligomer-induced neurotoxicity in rat neural stem cells (NSCs). Primary culture NSCs were treated with several concentrations of GV1001 and/or Aβ₂₅₋₃₅ oligomer for 48 hours. GV1001 protected NSCs against the Aβ₂₅₋₃₅ oligomer in a concentration-dependent manner. Aβ₂₅₋₃₅ concentration dependently decreased viability, proliferation, and mobilization of NSCs and GV1001 treatment restored the cells to wild-type levels. Aβ₂₅₋₃₅ increased free radical levels in rat NSCs while combined treatment with GV1001 significantly reduced these levels. In addition, GV1001 treatment of Aβ₂₅₋₃₅-injured NSCs increased the expression level of survival-related proteins, including mitochondria-associated survival proteins, and decreased the levels of death and inflammation-related proteins, including mitochondria-associated death proteins. Together, these results suggest that GV1001 possesses neuroprotective effects against Aβ₂₅₋₃₅ oligomer in NSCs and that these effects are mediated through mimicking the extra-telomeric functions of human telomerase reverse transcriptase, including the induction of cellular proliferation, anti-apoptotic effects, mitochondrial stabilization, and anti-aging and anti-oxidant effects.

100 Deals associated with KAEL-GemVax Co., Ltd.

Login to view more data

100 Translational Medicine associated with KAEL-GemVax Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 28 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

2

1

Approved

Other

4

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Tertomotide hydrochloride ( TERT )	Pancreatic Cancer More	Approved
MSI-vaccine(KAEL-GemVax)	Colorectal Cancer More	Phase 2
Ruxotemitide ( Mitochondrial proteins )	Sarcoma More	Phase 2
HIV vaccines polytope(KAEL-GemVax Co., Ltd.)	HIV Infections More	Discontinued
GV-1002	Pancreatic Cancer More	Pending